National Institute for Health and Care Excellence
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
Legend Biotech appoints new group of scientific advisors
The company is focused on CAR-T cell therapy to treat multiple myeloma
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
J&J receives positive NICE recommendation for multiple myeloma treatment
The treatment is approved for use within the NHS in England and Wales
Johnson & Jonson secures FDA approval for multiple myeloma treatment
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results